Skip to content

Efeect of local application of herbal preparation on vaginal discharges and inflammation of cervix

Comparative study of Bilva and Trivrit oil pichu in Cervicitis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013265
Enrollment
40
Registered
2018-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having signs and symptoms of Cervicitis

Interventions

Intervention1: Ayurvedic formulation Trivrita moola taila: Trivrita moola taila pichu 1HS Control Intervention1: Ayurvedic Formulation Bilva patra taila: Bilva patra taila pichu 1HS

Sponsors

Banaras Hindu University
Lead Sponsor
Nidhi Jain
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.All married women having signs and symptoms of Cervicitis- Mucopurulent vaginal discharge,Reddened and swollen cervix,Dyspareunia,Pruritis vulvae,Lower abdominal pain,frequent and painful micturition 2.Patient who will not use vaginal product during entire study. 3.Patient who will avoid sexual intercourse during entire study. 4.Patient who will follow the protocol. 5.Patients in which cervicitis is confirmed by pap smear test

Exclusion criteria

Exclusion criteria: Unmarried patients Any pathology of genital organs other than Cervicitis. Suspected pregnancy at screening or actively seeking pregnancy during study period. Serious underlying condition such as HIV or other primary or secondary immunosuppressive condition. H/O PID, ectopic pregnancy. Nursing mothers Psychiatric Patients Patients using hormonal preparation. Any specific or systemic diseases. Unable to follow the protocol

Design outcomes

Primary

MeasureTime frame
Complains- Vaginal discharge, dyspareunia, bleeding during coitus, backache, lower abdominal pain Sign- Cervical size, congestion, consistency, inflammation Investigation- Pap smear Timepoint: Total four follow ups will be done at 15 days interval, out of which 3 will be with medication and 4th will be without medication

Secondary

MeasureTime frame
Routine- CBC with ESR, Urine-R/M, FBS, HIV, VDRL Specific- Pap Smear, Urine- C/S, USG, HVS- C/S Timepoint: 45 days

Countries

India

Contacts

Public ContactProfessor Neelam

Banaras Hindu University

drneelamaditi@rediffmail.com09415618958

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026